BOSTON, MA September 17, 2026 — Ratio Therapeutics Inc. (“Ratio”) a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced the appointment of Kenan Turnacioglu, Ph.D., to its Board of Directors. Dr.